Ipca Laboratories Ltd NSE  /  BSE

Pharmaceuticals, Mid Cap

03 Dec 2021 | 04:14 PM

-32.20 (-1.55%)

Independent Research


We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts negative since 21-Apr-2020

    Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 21-Apr-2020 at a price of 1599.40.

  • Valuation Rating

    Fairly priced

    Based on its growth potential and our own criteria, at its current price the stock is fairly valued.

  • MT Tech Trend

    Trend positive since 31-Mar-2020

    The forty day Medium Term Technical Trend is positive since 31-Mar-2020. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 1454.891.

  • 4W REL Performance

    Under pressure (vs. SENSEX30)

    The four week relative underperformance versus SENSEX30 is -3.480.

Risk parameters

  • Risk Zone


    The stock has been on the low-sensitivity level since 20-Mar-2020.

  • Bear Market

    Below average sensitivity to market corrections

    On average, the stock has a tendency to minimize the drops in the index by -107%.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 359%.

  • Beta

    21 Low sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 21%.

  • Correlation

    0.15 Weak correlation to SENSEX30

    Stock movements are totally independent of index variations.

  • Value at Risk

    Rs.194.24 The medium term value at risk is estimated at 194.24 or 0.12000%

    The value at risk is estimated at 194.24. The risk is therefore 0.12000%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    21 Current year to 2022 annualized estimate

    The annualized growth estimate is for the current year to 2022.

  • P/E Ratio

    21.21 Estimated PE for 2022

    The estimated PE is for the year 2022.

  • G/PE Ratio

    1 10.051% discount to expected growth

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of 10.051%.

  • Dividend Yield

    0.22% Dividend is largely covered by profits

    The twelve month estimated dividend yield represents 4.701% of earnings forecasts.

  • Global Evaluation

    Slightly positive

    The stock is classified in the slightly positive zone since 20-Mar-2020.